Other News Releases in Biotechnology
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Other News Releases in Awards
Ryan Mallett, Jeremiah Masoli, Shane Vereen and Deunta Williams Announced as Week Twelve Nominees for the AT&T All-America Player of the Week Award
Mathematics and Materials Science Research Take Top Prize at Nation's Premier High School Science Competition
Biophysics and Chemistry Research Honored at Nation's Premier High School Science Competition
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Awards, Personnel Announcements
Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes
ANN ARBOR, Mich., Oct. 11 /PRNewswire/ -- Compendia Bioscience, Inc.
today announced the receipt of a $2.4 million SBIR Fast Track Award from
the National Cancer Institute to support the project entitled "Development
of Oncomine Professional as a Platform for Biopharmaceutical Research and
Development".
(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )
Compendia co-founder Dan Rhodes Ph.D., who will serve as the principal
investigator for this project, will assume a full time position at
Compendia Bioscience as Chief Executive Officer. Current CEO John Freshley
will remain with the company as Chief Business Officer overseeing sales,
marketing and corporate development.
"We are thrilled with this award from the NCI and are looking forward
to executing the project, which we expect will lead to increased
applicability of Oncomine Professional to drug discovery and development,"
said Dr. Rhodes. "And on a personal level, I am excited to have the
opportunity to increase my level of commitment to Compendia."
"Compendia was founded in 2006 to extend Oncomine the commercial
sector. Over the past year we have seen ever increasing acceptance of
Oncomine in the biopharmaceutical arena, and with that growing sales,
marketing, and business development demands," commented John Freshley. "I
am looking forward to concentrating on the continued commercial adaptation
of this important product."
Oncomine, a dynamic system that combines a rapidly growing compendium
of 20,000+ cancer transcriptome profiles with a sophisticated analysis
engine and a powerful web application for data mining and visualization,
facilitates rapid and reliable biomarker and therapeutic target discovery,
validation, and prioritization.
The NIH Fast-Track application process expedites award decisions and
funding of SBIR Phase II applications for scientifically meritorious
projects that have a high potential for commercialization. The Fast-Track
process allows Phase I and II grant applications to be submitted and
reviewed together.
About Compendia Bioscience, Inc. Compendia Bioscience is dedicated to
harnessing the global collection of high throughput molecular data to
provide researchers with the data and analysis tools necessary to validate
biomarker and gene target discoveries, better understand mechanisms of
disease, and optimize clinical outcomes."
SOURCE Compendia Bioscience, Inc.